[go: up one dir, main page]

EA200300050A1 - Гликопептидфосфонатные производные - Google Patents

Гликопептидфосфонатные производные

Info

Publication number
EA200300050A1
EA200300050A1 EA200300050A EA200300050A EA200300050A1 EA 200300050 A1 EA200300050 A1 EA 200300050A1 EA 200300050 A EA200300050 A EA 200300050A EA 200300050 A EA200300050 A EA 200300050A EA 200300050 A1 EA200300050 A1 EA 200300050A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
glykopeptidphosphonate
glycopeptide
phosphonogroup
glycopeptides
Prior art date
Application number
EA200300050A
Other languages
English (en)
Other versions
EA005953B1 (ru
Inventor
Майкл Р. Лидбэттер
Мартин С. Линселл
Original Assignee
Тереванс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тереванс, Инк. filed Critical Тереванс, Инк.
Publication of EA200300050A1 publication Critical patent/EA200300050A1/ru
Publication of EA005953B1 publication Critical patent/EA005953B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Описаны производные гликопептидов, замещенные одним или более заместителями, включающими одну или более фосфоногрупп, и фармацевтические композиции, содержащие указанные гликопептидные производные. Описанные гликопептидные производные полезны в качестве антибактериальных средств.Отчет о международном поиске был опубликован 2002.04.11.
EA200300050A 2000-06-22 2001-05-01 Гликопептидфосфонатные производные EA005953B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21341000P 2000-06-22 2000-06-22
PCT/US2001/013998 WO2001098328A2 (en) 2000-06-22 2001-05-01 Glycopeptide phosphonate derivatives

Publications (2)

Publication Number Publication Date
EA200300050A1 true EA200300050A1 (ru) 2003-04-24
EA005953B1 EA005953B1 (ru) 2005-08-25

Family

ID=22795013

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300050A EA005953B1 (ru) 2000-06-22 2001-05-01 Гликопептидфосфонатные производные

Country Status (36)

Country Link
US (10) US6635618B2 (ru)
EP (1) EP1292612B1 (ru)
JP (2) JP3900491B2 (ru)
KR (1) KR100768488B1 (ru)
CN (1) CN100469788C (ru)
AR (1) AR035333A1 (ru)
AT (1) ATE337334T1 (ru)
AU (2) AU6110701A (ru)
BR (1) BRPI0111222B8 (ru)
CA (2) CA2411590C (ru)
CY (2) CY1105194T1 (ru)
CZ (1) CZ303672B6 (ru)
DE (2) DE60122516T2 (ru)
DK (1) DK1292612T3 (ru)
EA (1) EA005953B1 (ru)
EG (1) EG26726A (ru)
ES (1) ES2271012T3 (ru)
HK (1) HK1052191B (ru)
HR (1) HRP20020888B1 (ru)
HU (2) HU229370B1 (ru)
IL (1) IL152408A (ru)
IS (1) IS2303B (ru)
LU (1) LU91908I2 (ru)
MX (1) MXPA02012745A (ru)
MY (1) MY127081A (ru)
NO (2) NO330360B1 (ru)
NZ (1) NZ522279A (ru)
PL (1) PL207101B1 (ru)
PT (1) PT1292612E (ru)
RS (1) RS50499B (ru)
SI (1) SI1292612T1 (ru)
SK (1) SK287470B6 (ru)
TW (1) TWI305209B (ru)
UA (1) UA75083C2 (ru)
WO (1) WO2001098328A2 (ru)
ZA (1) ZA200209419B (ru)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2201825T3 (es) * 1998-12-23 2004-03-16 Theravance, Inc. Derivados del glicopeptidos y composiciones farmaceuticas que los contienen.
US6770621B2 (en) 2000-05-02 2004-08-03 Theravance, Inc. Polyacid glycopeptide derivatives
ATE416791T1 (de) * 2000-05-02 2008-12-15 Theravance Inc Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
US6872804B2 (en) 2000-06-22 2005-03-29 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
WO2001098329A1 (en) 2000-06-22 2001-12-27 Theravance, Inc. Polyhydroxy glycopeptide derivatives
UA75083C2 (ru) * 2000-06-22 2006-03-15 Тераванс, Інк. Производные гликопептидфосфонатов
WO2001098327A2 (en) 2000-06-22 2001-12-27 Theravance, Inc. Glycopeptide carboxy-saccharide derivatives
TWI233932B (en) * 2001-08-24 2005-06-11 Theravance Inc Process for purifying glycopeptide phosphonate derivatives
TWI275594B (en) * 2001-08-24 2007-03-11 Theravance Inc Process for preparing vancomycin phosphonate derivatives
TWI312785B (en) * 2001-08-24 2009-08-01 Theravance Inc Process for preparing vancomycin derivatives
EP1507796B1 (en) * 2002-05-24 2012-05-02 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
WO2003106399A2 (en) 2002-06-17 2003-12-24 Theravance, Inc. PROCESS FOR PREPARING N-PROTECTED β-AMINO ALDEHYDE COMPOUNDS
US7521418B2 (en) * 2003-05-27 2009-04-21 Theravance, Inc. Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent
ATE381957T1 (de) * 2003-07-22 2008-01-15 Theravance Inc Verwendung eines antimykotischen echinocandin- mittels in kombination mit einem antibakteriellen glycopeptid-mittel
TWI342312B (en) * 2003-10-22 2011-05-21 Theravance Inc Hydrochloride salts of a glycopeptide phosphonate derivative
JP2009526755A (ja) * 2006-01-10 2009-07-23 ユー， リュイ ジェイ． Ｎ−（ホスホノアルキル）−アミノ酸、その誘導体及び組成物及びその利用法
JP2008112847A (ja) * 2006-10-30 2008-05-15 Shin Etsu Chem Co Ltd 単結晶シリコン太陽電池の製造方法及び単結晶シリコン太陽電池
AU2007336674A1 (en) 2006-12-22 2008-07-03 Targanta Therapeutics, Inc. Phosphonated glycopeptide and lipoglycopeptide antibiotics and uses thereof for the prevention and treatment of bone and joint infections
US20090069219A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched telavancin
EP2217224B1 (en) * 2007-11-09 2019-05-08 Basf As Lipid compounds for use in cosmetic products, as food supplement or as a medicament
KR20100109936A (ko) * 2007-12-26 2010-10-11 리드 테라퓨틱스, 인크. 항박테리아제로서의 신규한 반(半)-합성 글리코펩티드
EP2147910A1 (en) 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
WO2010048340A2 (en) * 2008-10-24 2010-04-29 Lead Therapeutics, Inc. Novel semi-synthetic glycopeptides as antibacterial agents
GB2465863A (en) * 2008-12-05 2010-06-09 Lead Therapeutics Inc Semi-synthetic heptapeptidic glycopeptides for the treatment of bacterial infections
WO2010129233A2 (en) 2009-04-28 2010-11-11 Targanta Therapeutics Corp. Methods of treating bacterial infections using oritavancin
EA021177B1 (ru) 2009-05-08 2015-04-30 Пронова Биофарма Норге Ас Полиненасыщенные жирные кислоты для лечения заболеваний, связанных с сердечно-сосудистыми, метаболическими и воспалительными заболеваниями
US20110009596A1 (en) * 2009-07-09 2011-01-13 Plus Chemicals Sa Process for the preparation of n-protected-decylaminoethanal
ES2618604T3 (es) 2010-11-05 2017-06-21 Pronova Biopharma Norge As Métodos de tratamiento usando compuestos lipídicos
WO2013034676A1 (en) 2011-09-09 2013-03-14 Sandoz Ag Process for the synthesis of telavancin, its pharmaceutically acceptable salts as well as an n-protected imine-derivative of telavancin
EP2753638A1 (en) 2011-09-09 2014-07-16 Sandoz AG Process for the synthesis of telavancin and its pharmaceutically acceptable salts as well as n-protected derivatives thereof
JP5724937B2 (ja) * 2012-04-23 2015-05-27 ニプロ株式会社 腎臓集積性を示すペプチド、製剤
CN103897040B (zh) * 2012-12-27 2018-05-22 浙江医药股份有限公司新昌制药厂 新型糖肽类化合物或其药用盐及其制备方法、以及药物组合物和用途
KR102213143B1 (ko) 2013-02-28 2021-02-08 바스프 에이에스 지방질 화합물, 트리글리세리드 및 계면활성제를 포함하는 조성물 및 이를 이용하는 방법
TWI641372B (zh) 2013-03-15 2018-11-21 美商梅琳塔有限責任公司 使用抗生素治療超重和肥胖患者感染的方法
CN105085636B (zh) * 2014-05-19 2020-05-01 中国医学科学院药物研究所 一类万古霉素衍生物、其制备方法及其在抗菌方面的应用
HK1245644B (en) 2015-02-23 2019-12-06 Cumberland Pharmaceuticals Inc. Doses and methods of administering telavancin
KR102644400B1 (ko) 2015-04-28 2024-03-06 바스프 에이에스 비알코올성 지방간염의 예방 및/또는 치료를 위한 구조적으로 강화된 함황 지방산의 용도
CN106188243B (zh) * 2015-05-05 2020-06-26 博瑞生物医药（苏州）股份有限公司 一种奥利万星的制备方法
US20200171124A1 (en) 2016-04-15 2020-06-04 Lupin Limited Topical compositions for ophthalmic and otic use
EP3454883A1 (en) * 2016-05-09 2019-03-20 Xellia Pharmaceuticals ApS Stabilized glycopeptide antibiotic formulations
JP7210476B2 (ja) * 2017-05-22 2023-01-23 インスメッド インコーポレイテッド リポ‐グリコペプチド可切断性誘導体及びその使用
CN107629115B (zh) * 2017-09-08 2021-05-07 福建省微生物研究所 一种特拉万星的纯化方法
CN107629116B (zh) * 2017-09-08 2021-05-07 福建省微生物研究所 一种特拉万星的纯化方法
CN107987131B (zh) * 2017-11-16 2021-03-09 上海来益生物药物研究开发中心有限责任公司 一组具有抗耐药性细菌活性的化合物、其制备方法和应用
US11925614B2 (en) 2017-12-06 2024-03-12 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
CN108409837B (zh) 2018-03-06 2021-09-24 上海来益生物药物研究开发中心有限责任公司 一组具有抗耐药性细菌活性的糖肽类化合物、其制备方法和应用
EP3883589A4 (en) * 2018-11-21 2022-05-25 Insmed Incorporated LIPO-GLYCOPEPTIDE CLEAVABLE DERIVATIVES AND USES THEREOF

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872A (en) * 1849-11-13 Means of changing the combination in bevolving tumbler-locks
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4698327A (en) 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
US4643987A (en) 1985-08-14 1987-02-17 Eli Lilly And Company Modified glycopeptides
US4639433A (en) * 1985-08-14 1987-01-27 Eli Lilly And Company Glycopeptide derivatives
US4885275A (en) * 1987-10-15 1989-12-05 Eli Lilly And Company Vancomycin-HCL solutions and the lyophilization thereof
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
CA2031803C (en) 1989-12-13 2001-05-29 Ramakrishnan Nagarajan Improvements in or relating to glycopeptide deriveratives
US5750509A (en) 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926
US5217493A (en) * 1992-03-11 1993-06-08 Board Of Regents, The University Of Texas System Antibacterial coated medical implants
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
EP0674528A4 (en) 1992-12-02 1996-06-26 Insite Vision Inc DRUG DELIVERY SYSTEM BASED ON CYCLODEXTRIN AND A POLYMER.
US6077822A (en) * 1993-09-14 2000-06-20 Dumex-Alpharma A/S Drug salts
US5840684A (en) * 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
PE40996A1 (es) 1994-01-28 1996-10-14 Lilly Co Eli Derivado de antibiotico de glucopeptido
US5614615A (en) * 1995-03-21 1997-03-25 The Scripps Research Institute Sialyl Lewis X mimetics incorporating fucopeptides
US5919756A (en) 1996-06-28 1999-07-06 Eli Lilly And Company Amides
WO1999017793A1 (en) * 1997-10-03 1999-04-15 Fujisawa Pharmaceutical Co., Ltd. Hydrochlorides of vancomycin antibiotics and process for producing the same
US5916873A (en) 1997-04-17 1999-06-29 Eli Lilly And Company Teicoplanin derivatives
US6323176B1 (en) * 1998-02-25 2001-11-27 Eli Lilly And Company Cyclic peptide antifungal agents
EP1095058A4 (en) * 1998-07-14 2003-07-16 Univ Princeton GLYCOPEPTIDANTIBIOTICS, COMBINATIONAL LIBRARIES OF GLYCOPEPTIDANTIBIOTICS AND METHOD FOR THEIR PRODUCTION
ES2201825T3 (es) * 1998-12-23 2004-03-16 Theravance, Inc. Derivados del glicopeptidos y composiciones farmaceuticas que los contienen.
DE19911097A1 (de) 1999-03-12 2000-09-14 Basf Ag Verfahren zur Herstellung von festen cyclodextrinhaltigen Dosierungsformen
CA2370782A1 (en) 1999-04-02 2000-10-12 The Trustees Of Princeton University Desleucyl glycopeptide antibiotics and methods of making same
JP2000302687A (ja) 1999-04-22 2000-10-31 Sagami Chem Res Center 抗菌性オリゴマー及び抗菌剤
ATE416791T1 (de) 2000-05-02 2008-12-15 Theravance Inc Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
US6770621B2 (en) 2000-05-02 2004-08-03 Theravance, Inc. Polyacid glycopeptide derivatives
AU2001267011B2 (en) 2000-06-21 2006-02-02 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents
WO2001098329A1 (en) 2000-06-22 2001-12-27 Theravance, Inc. Polyhydroxy glycopeptide derivatives
WO2001098327A2 (en) 2000-06-22 2001-12-27 Theravance, Inc. Glycopeptide carboxy-saccharide derivatives
WO2001098326A2 (en) 2000-06-22 2001-12-27 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
UA75083C2 (ru) * 2000-06-22 2006-03-15 Тераванс, Інк. Производные гликопептидфосфонатов
TWI275594B (en) * 2001-08-24 2007-03-11 Theravance Inc Process for preparing vancomycin phosphonate derivatives
TWI233932B (en) * 2001-08-24 2005-06-11 Theravance Inc Process for purifying glycopeptide phosphonate derivatives

Also Published As

Publication number Publication date
CY1105194T1 (el) 2010-03-03
US7700550B2 (en) 2010-04-20
UA75083C2 (ru) 2006-03-15
YU96902A (sh) 2006-01-16
MY127081A (en) 2006-11-30
KR100768488B1 (ko) 2007-10-18
AU2001261107B2 (en) 2006-07-20
EA005953B1 (ru) 2005-08-25
US8859506B2 (en) 2014-10-14
US7351691B2 (en) 2008-04-01
US20070049519A1 (en) 2007-03-01
NO20025954D0 (no) 2002-12-11
US8101575B2 (en) 2012-01-24
CA2713965A1 (en) 2001-12-27
SK18522002A3 (sk) 2003-06-03
CY2012006I1 (el) 2016-06-22
KR20030032970A (ko) 2003-04-26
ES2271012T3 (es) 2007-04-16
JP2004501161A (ja) 2004-01-15
IS6600A (is) 2002-10-29
HUS1400024I1 (hu) 2017-03-28
EP1292612A2 (en) 2003-03-19
BRPI0111222B8 (pt) 2021-05-25
DE60122516T2 (de) 2007-01-04
HK1052191A1 (en) 2003-09-05
US20050164916A1 (en) 2005-07-28
CZ303672B6 (cs) 2013-02-20
US20120283195A1 (en) 2012-11-08
CA2411590A1 (en) 2001-12-27
NO20025954L (no) 2002-12-11
TWI305209B (en) 2009-01-11
ZA200209419B (en) 2004-02-19
HU229370B1 (hu) 2013-11-28
US20060063706A1 (en) 2006-03-23
EG26726A (en) 2014-06-18
HUP0301320A3 (en) 2007-05-29
CZ20023942A3 (cs) 2003-03-12
US20100160211A1 (en) 2010-06-24
SK287470B6 (sk) 2010-10-07
DE60122516D1 (de) 2006-10-05
BRPI0111222B1 (pt) 2015-03-17
IS2303B (is) 2007-10-15
CN1437611A (zh) 2003-08-20
NO2011025I2 (ru) 2011-11-18
US20140024604A1 (en) 2014-01-23
CA2411590C (en) 2010-10-19
LU91908I2 (fr) 2012-01-30
WO2001098328A2 (en) 2001-12-27
US6887976B2 (en) 2005-05-03
US20080312407A1 (en) 2008-12-18
US20020022590A1 (en) 2002-02-21
PL207101B1 (pl) 2010-11-30
US7208471B2 (en) 2007-04-24
SI1292612T1 (sl) 2006-12-31
PT1292612E (pt) 2006-12-29
CN100469788C (zh) 2009-03-18
US20030207797A1 (en) 2003-11-06
IL152408A0 (en) 2003-05-29
JP3900491B2 (ja) 2007-04-04
HUP0301320A2 (hu) 2003-08-28
HK1052191B (en) 2007-01-26
HRP20020888B1 (en) 2007-12-31
US7008923B2 (en) 2006-03-07
PL359419A1 (en) 2004-08-23
US20040063916A1 (en) 2004-04-01
NZ522279A (en) 2004-07-30
US6635618B2 (en) 2003-10-21
US8541375B2 (en) 2013-09-24
JP2007045842A (ja) 2007-02-22
RS50499B (sr) 2010-03-02
NO2011025I1 (no) 2011-11-18
AR035333A1 (es) 2004-05-12
IL152408A (en) 2009-05-04
US6872701B2 (en) 2005-03-29
NO330360B1 (no) 2011-04-04
WO2001098328A3 (en) 2002-04-11
HRP20020888A2 (en) 2005-02-28
AU6110701A (en) 2002-01-02
MXPA02012745A (es) 2004-04-05
BR0111222A (pt) 2003-04-01
CY2012006I2 (el) 2016-06-22
DE122011100062I1 (de) 2012-03-15
ATE337334T1 (de) 2006-09-15
EP1292612B1 (en) 2006-08-23
DK1292612T3 (da) 2007-01-02

Similar Documents

Publication Publication Date Title
EA200300050A1 (ru) Гликопептидфосфонатные производные
PT1140993E (pt) Derivados de glicopeptidos e composicoes farmaceuticas contendo os mesmos
EA200200938A1 (ru) Фармацевтические композиции, содержащие производные азетидина, новые производные азетидина и их получение
EA200100411A1 (ru) Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
EA200100412A1 (ru) Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
EA199900373A2 (ru) Фармацевтические композиции
EA200201179A1 (ru) Производные 2-аминокарбонил-9h-пурина
EA200400432A1 (ru) Производные мочевины
HRP20030383B1 (hr) Laktamski spoj
EA200200479A1 (ru) Новые олигосахариды, их получение и содержащие их фармацевтические композиции
ES2243579T3 (es) Derivados de pirazolopirideno.
DK0920421T3 (da) Isoxazolinderivater anvendelige som antimikrobielle midler
ATE222115T1 (de) Verbesserung der antibakteriellen wirkung von oxazolidinon durch arginin derivate
EA200300392A1 (ru) Производные пиперазина с мостиковой связью
EA200501341A1 (ru) Противобактериальные индолоноксазолидиноны, промежуточные соединения для их получения и содержащие их фармацевтические композиции
DK1089625T3 (da) Ektoparasiticide midler
ES2178765T3 (es) Nuevos derivados de 1,7,7-trimetil-biciclo (2.2.1) heptano.
DK1073447T3 (da) N1-modificerede glycopeptider
EA200100984A1 (ru) Новые кристаллические формы макролидного антибиотика
EA200400822A1 (ru) Производные 3,4-дигидро-1h-изохинолин-2-ила
EA200400670A1 (ru) Фармацевтические композиции, содержащие 3,4-пропинопергидропурины, и их применение для блокирования нейронной передачи
EA200301062A1 (ru) Фармацевтические комбинации на основе производных пиридоиндолона и противораковых агентов
PT1140932E (pt) Derivados de 1,8-benzonaftiridina
TWI231815B (en) Glycopeptide derivatives and pharmaceutical compositions containing the same for use as antibacterial agents
CY1110529T1 (el) Παρασκευη ν-υποκατεστημενων 2,7-διαλκυλο-4-υδροξυ-5-αμινο-8-αρυλοοκτανοϋλαμιδιων

Legal Events

Date Code Title Description
QB4A Registration of a licence in a contracting state
QB4A Registration of a licence in a contracting state
PC4A Registration of transfer of a eurasian patent by assignment
QB4A Registration of a licence in a contracting state
QB4A Registration of a licence in a contracting state
QB4A Registration of a licence in a contracting state
ND4A Extension of term of a eurasian patent
TK4A Corrections in published eurasian patents
PC4A Registration of transfer of a eurasian patent by assignment
MK4A Patent expired

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU